Cancer incidence in a population of Jewish women at risk of ovarian cancer

Journal of Clinical Oncology

Volumn 20, Issue 6, 2002, Pages 1570-1577

  Liede, Alexander ^a   Karlan, Beth Y ^a   Baldwin, Rae Lynn ^a   Platt, Lawrence D ^a   Kuperstein, Graciela ^a   Narod, Steven A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; EARLY DIAGNOSIS; FAMILY HISTORY; FEMALE; GENE MUTATION; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; JEW; MAJOR CLINICAL STUDY; ONCOGENE; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; UNITED STATES; UTERINE TUBE TUMOR;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; FOUNDER EFFECT; GENE FREQUENCY; GENES, BRCA1; GENETIC SCREENING; HUMANS; INCIDENCE; JEWS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 0037087579     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.6.1570     Document Type: Article

References (33)

1. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer
2. Risk factors for breast cancer
3. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2
4. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals
5. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews
6. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women
7. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: Frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families
8. Frequency of the BRCA1 185delAG mutation among Jewish women with ovarian cancer and matched population controls
9. High frequency of BRCA1 185delAG mutation in ovarian cancer in Israel: National Israel Study of Ovarian Cancer
10. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer
11. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation
12. Recommendations for follow-up care of individuals with an inherited predisposition to cancer: II. BRCA1 and BRCA2. Cancer
13. The performance of screening tests for ovarian cancer: Results of a systematic review
14. Risks of cancer in BRCA1 mutation carriers: Breast Cancer Linkage Consortium
15. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2
16. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer
17. A multidisciplinary approach to the early detection of ovarian carcinoma: Rationale, protocol design, and early results
18. A rapid fluorescent multiplexed-PCR analysis (FMPA) for founder mutations in the BRCA1 and BRCA2 genes
19. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations
20. Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: Implications for ovarian cancer screening
21. BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum
22. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families
23. Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations
24. Fallopian tube cancer as a feature of BRCA1-associated syndromes
25. Cancer risks in BRCA2 mutation carriers: The Breast Cancer Linkage Consortium
26. A genetic epidemiological study of carcinoma of the fallopian tube
27. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation
28. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk
29. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation
30. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers
31. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study - Hereditary Breast Cancer Clinical Study Group